1-((furo[3,2-c]pyridine-2-yl-carbonyl)-3-(3-fluro-4-piperidin-1-yl)phenyl)-thiourea | 860618-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1-((furo[3,2-c]pyridine-2-yl-carbonyl)-3-(3-fluro-4-piperidin-1-yl)phenyl)-thiourea
• 英文别名: N-[(3-fluoro-4-piperidin-1-ylphenyl)carbamothioyl]furo[3,2-c]pyridine-2-carboxamide
• CAS: 860618-14-0
• 化学式: C₂₀H₁₉FN₄O₂S
• 分子量: 398.461
• InChiKey: XLOBOIRDODREEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Azabenzofuran substituted thioureas; inhibitors of viral replication
  申请人：Thurkauf Andrew

  公开号：US20050228013A1

  公开（公告）日：2005-10-13

  The present invention provides compounds of Formula 1, wherein the variables Ar, A 1 , A 2 , A 3 , A 4 , R 5 , R 6 , R 7 , V, W. X, and Y are defined herein. Certain compounds of Formula 1 described herein possess potent antiviral activity. The invention also provides compounds of Formula 1 that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula 1, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula 1 effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula 1 as a single active agent or administering a compound of Formula 1 in combination with on or more other therapeutic agent.

  本发明提供了一种1式化合物，其中变量Ar、A1、A2、A3、A4、R5、R6、R7、V、W、X和Y的定义如本文所述。本文描述了某些1式化合物具有强效的抗病毒活性。本发明还提供了1式化合物，它们是强效和/或选择性的丙型肝炎病毒复制抑制剂。本发明还提供了含有一种或多种1式化合物、或该类化合物的盐、溶剂化合物或酰化前药和一种或多种药学上可接受的载体、辅料或稀释剂的制药组合物。本发明还包括通过向患有某些传染性疾病的患者施用有效量的1式化合物来治疗患者的方法。这些传染性疾病包括病毒感染，特别是HCV感染。本发明特别包括治疗患有传染性疾病的人类患者的方法，但也包括治疗患有传染性疾病的其他动物，包括家畜和驯养的伴侣动物的方法。治疗方法包括将1式化合物作为单一活性剂或将1式化合物与一种或多种其他治疗剂组合使用。
• AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：EP1709047A2

  公开（公告）日：2006-10-11
• JP2007517887A
  申请人：——

  公开号：JP2007517887A

  公开（公告）日：2007-07-05
• US7439374B2
  申请人：——

  公开号：US7439374B2

  公开（公告）日：2008-10-21
• [EN] AZABENZOFURAN SUBSTITUTED THIOUREAS; INHIBITORS OF VIRAL REPLICATION<br/>[FR] THIOUREES A SUBSTITUTION AZABENZOFURANE UTILISEES EN TANT QU'INHIBITEURS DE REPLICATION VIRALE
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2005067900A2

  公开（公告）日：2005-07-28

  The present invention provides compounds of Formula: (1), wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula (1) described herein possess potent antiviral activity. The invention also provides compounds of Formula (1) that are potent and/ or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compounds of Formula (1), or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula (1) effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula (1) as a single active agent or administering a compound of Formula (1) in combination with on or more other therapeutic agent.